These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38199141)

  • 1. Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease.
    Huang W; Cao Z; Wang W; Yang Z; Jiao S; Chen Y; Chen S; Zhang L; Li Z
    Bioorg Chem; 2024 Feb; 143():107071. PubMed ID: 38199141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis.
    Mo C; Xu X; Zhang P; Peng Y; Zhao X; Chen S; Guo F; Xiong Y; Chu XJ; Xu X
    J Med Chem; 2023 Jul; 66(14):9363-9375. PubMed ID: 37424079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver.
    Qiu Q; Wang W; Zhao X; Chen Y; Zhao S; Zhu J; Xu X; Geng R
    Bioorg Chem; 2020 Nov; 104():104262. PubMed ID: 32919135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hammerhead-type FXR agonists induce an enhancer RNA
    Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper J
    Elife; 2024 Apr; 13():. PubMed ID: 38619504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
    Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B
    J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
    Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C
    Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.
    Ren Q; Chen Y; Zhou Z; Cai Z; Jiao S; Huang W; Wang B; Chen S; Wang W; Cao Z; Yang Z; Deng L; Hu L; Zhang L; Li Z
    J Med Chem; 2023 May; 66(9):6082-6104. PubMed ID: 37079895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists.
    Wang W; Cao Z; Yang Z; Chen Y; Yao H; Zhou D; Ou P; Huang W; Jiao S; Chen S; Chen L; Liu Y; Mao J; Xie J; Xiang R; Yang Y; Chen Y; Yang Y; Tan L; Tang H; Zhang L; Li Z
    Eur J Med Chem; 2023 Oct; 258():115614. PubMed ID: 37413879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
    Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
    J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
    Zhu Y; Zhang J; Min F; Yang X; Li L; Zhang Y; Hou X; Fang H
    Bioorg Med Chem Lett; 2022 Nov; 76():128993. PubMed ID: 36130662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesoid X receptor modulators 2014-present: a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist.
    Moon AN; Briand F; Breyner N; Song DK; Madsen MR; Kim H; Choi K; Lee Y; Namkung W
    Biomed Pharmacother; 2024 Apr; 173():116331. PubMed ID: 38428307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
    Wang K; Zhang Y; Wang G; Hao H; Wang H
    Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.